Research Article

Betulinic Acid Mitigates Estrogen Deficiency–Related Femoral Bone Loss: Evidence from an Ovariectomized Rat Model

Number: Advanced Online Publication Early Pub Date: April 27, 2026

Betulinic Acid Mitigates Estrogen Deficiency–Related Femoral Bone Loss: Evidence from an Ovariectomized Rat Model

Abstract

Objective: Postmenopausal osteoporosis (OP) is characterized by estrogen deficiency–induced bone loss and deterioration of trabecular microarchitecture. Betulinic acid (BA), a natural pentacyclic triterpenoid, has demonstrated antioxidant and osteoprotective properties. This study aimed to evaluate the histopathological effects of BA on femoral bone tissue in ovariectomized rats. Methods: Thirty-two female Wistar albino rats were randomly divided into four groups (n=8): Sham, OVX, BA+OVX (BA administered before OVX), and OVX+BA (BA administered after OVX). BA was given orally at 3 mg/kg/day. Pelvic bone mineral density (BMD) was assessed using dual-energy X-ray absorptiometry (DEXA). Serum calcium levels were measured, and femoral bone tissues were evaluated histopathologically for trabecular thinning and loss of connectivity. Results: OVX resulted in a significant reduction in pelvic BMD and marked deterioration of trabecular bone architecture compared with the Sham group. BA administration prior to OVX significantly attenuated OVX-induced bone loss, as evidenced by higher pelvic BMD and preserved trabecular structure compared with the OVX group (p<.05). In contrast, BA treatment initiated after OVX did not significantly reverse bone loss or histopathological damage. Serum calcium levels did not differ significantly among the groups. Conclusion: BA exerts a protective effect against OVX-induced bone loss when administered prior to estrogen deficiency, preserving both bone mineral density and trabecular microarchitecture. These findings suggest that BA may have a preventive, rather than therapeutic, role in estrogen deficiency–related (OP).

Keywords

Supporting Institution

TUBITAK

Project Number

TUBITAK Grant Agreement No : 1919B011700680

Ethical Statement

Ethics committee approval was received for this study from the ethics committee of İnönü University (Date: March 29, 2016, Number: 2016/A-47).

References

  1. Aeimlapa, R., Wongdee, K., Tiyasatkulkovit, W., Kengkoom, K., Krishnamra, N., & Charoenphandhu, N. (2019). Anomalous bone changes in ovariectomized type-2 diabetic rats: inappropriately low bone turnover with bone loss in an estrogen-deficient condition. American Journal of Physiology. Endocrinology and Metabolism, 317(4), E646-E657. https://doi.org/10.1152/ajpendo.00093.2019
  2. Anish, R., Soumya, N., Nair, A., & Rauf, A. (2023). Standardization of Sprague-Dawley rats as a postmenopausal osteoporotic model through biochemical marker evaluation and Dexa scan. Exploratory Animal and Medical Research, 13(1), 39-48. https://doi.org/10.52635/eamr/13.1.39-48
  3. Arslan, A. K., Yaşar, Ş., Çolak, C., & Yoloğlu, S. (2018). R Shiny Paketi ile Kruskal Wallis H Testi için İnteraktif Bir Web Uygulaması [An Interactive Web Application for Kruskal Wallis H Test with R Shiny]. Annals of Health Sciences Research, 7(2), 49-55.
  4. Atwa, A., Mostafa, M., Song, S.-J., & Sarhan, M. (2021). The Femoral Head Epiphysis of Ovariectomized Rats as A Site for Studies on Osteoporosis: Microstructural Changes Evaluations. Egyptian Academic Journal of Biological Sciences, 13, 1-12. https://doi.org/10.21608/eajbsd.2021.145983
  5. Bilgiç, Y., Alkuş, H., Özhan, O., Üremiş, M. M., Vardı, N., Arslan, A. K.,…Türköz, Y. (2022). Protective and Therapeutic Effects of Betulinic Acid on Acetic Acid-Induced Experimental Colitis Model. Journal of Enterocolitis, 1, 6-11. https://doi.org/10.5152/Jenterocolitis.2022.220203
  6. Boyd, S., Davison, P., Müller, R., & Gasser, J. (2006). Monitoring individual morphological changes over time in ovariectomized rats by in vivo micro-computed tomography. Bone, 39(4), 854-862. https://doi.org/10.1016/j.bone.2006.04.017
  7. Campbell, G., Buie, H., & Boyd, S. (2008). Signs of irreversible architectural changes occur early in the development of experimental osteoporosis as assessed by in vivo micro-CT. Osteoporosis International, 19, 1409-1419. https://doi.org/10.1007/s00198-008-0581-7
  8. Cheng, C., Chen, L.-R., & Chen, K.-H. (2022). Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover. International Journal of Molecular Sciences, 23(3), 1376. https://doi.org/10.3390/ijms23031376

Details

Primary Language

English

Subjects

Medical Pharmacology

Journal Section

Research Article

Early Pub Date

April 27, 2026

Publication Date

-

Submission Date

January 26, 2026

Acceptance Date

April 20, 2026

Published in Issue

Year 2026 Number: Advanced Online Publication

APA
Özhan, O., Sahin, H., Korkmaz, M. F., Yıldız, A., Kekilli, E., Vardı, N., & Parlakpınar, H. (2026). Betulinic Acid Mitigates Estrogen Deficiency–Related Femoral Bone Loss: Evidence from an Ovariectomized Rat Model. Recent Trends in Pharmacology, Advanced Online Publication. https://doi.org/10.62425/rtpharma.1871984
AMA
1.Özhan O, Sahin H, Korkmaz MF, et al. Betulinic Acid Mitigates Estrogen Deficiency–Related Femoral Bone Loss: Evidence from an Ovariectomized Rat Model. Recent Trends in Pharmacology. 2026;(Advanced Online Publication). doi:10.62425/rtpharma.1871984
Chicago
Özhan, Onural, Hilal Sahin, Mehmet Fatih Korkmaz, et al. 2026. “Betulinic Acid Mitigates Estrogen Deficiency–Related Femoral Bone Loss: Evidence from an Ovariectomized Rat Model”. Recent Trends in Pharmacology, no. Advanced Online Publication. https://doi.org/10.62425/rtpharma.1871984.
EndNote
Özhan O, Sahin H, Korkmaz MF, Yıldız A, Kekilli E, Vardı N, Parlakpınar H (April 1, 2026) Betulinic Acid Mitigates Estrogen Deficiency–Related Femoral Bone Loss: Evidence from an Ovariectomized Rat Model. Recent Trends in Pharmacology Advanced Online Publication
IEEE
[1]O. Özhan et al., “Betulinic Acid Mitigates Estrogen Deficiency–Related Femoral Bone Loss: Evidence from an Ovariectomized Rat Model”, Recent Trends in Pharmacology, no. Advanced Online Publication, Apr. 2026, doi: 10.62425/rtpharma.1871984.
ISNAD
Özhan, Onural - Sahin, Hilal - Korkmaz, Mehmet Fatih - Yıldız, Azibe - Kekilli, Ersoy - Vardı, Nigar - Parlakpınar, Hakan. “Betulinic Acid Mitigates Estrogen Deficiency–Related Femoral Bone Loss: Evidence from an Ovariectomized Rat Model”. Recent Trends in Pharmacology. Advanced Online Publication (April 1, 2026). https://doi.org/10.62425/rtpharma.1871984.
JAMA
1.Özhan O, Sahin H, Korkmaz MF, Yıldız A, Kekilli E, Vardı N, Parlakpınar H. Betulinic Acid Mitigates Estrogen Deficiency–Related Femoral Bone Loss: Evidence from an Ovariectomized Rat Model. Recent Trends in Pharmacology. 2026. doi:10.62425/rtpharma.1871984.
MLA
Özhan, Onural, et al. “Betulinic Acid Mitigates Estrogen Deficiency–Related Femoral Bone Loss: Evidence from an Ovariectomized Rat Model”. Recent Trends in Pharmacology, no. Advanced Online Publication, Apr. 2026, doi:10.62425/rtpharma.1871984.
Vancouver
1.Onural Özhan, Hilal Sahin, Mehmet Fatih Korkmaz, Azibe Yıldız, Ersoy Kekilli, Nigar Vardı, Hakan Parlakpınar. Betulinic Acid Mitigates Estrogen Deficiency–Related Femoral Bone Loss: Evidence from an Ovariectomized Rat Model. Recent Trends in Pharmacology. 2026 Apr. 1;(Advanced Online Publication). doi:10.62425/rtpharma.1871984